Granules gets USFDA nod for Acetaminophen, Aspirin and Caffeine tablets

The product would be manufactured at our Hyderabad facility and is expected to be launched shortly.

63
Medicine Tablet
Picture: Pixabay

Last Updated on February 26, 2021 by The Health Master

Granules India has received the US Food & Drug Administration (USFDA) approval of its Abbreviated New Drug Application (ANDA) for Acetaminophen, Aspirin and Caffeine Tablets USP, 250 mg/250 mg/65 mg (OTC).

It is bioequivalent to the reference listed drug product (RLD), Excedrin Migraine Tablets, 250 mg/250 mg/65 mg, of GlaxoSmithKline Consumer Healthcare.

The product would be manufactured at our Hyderabad facility and is expected to be launched shortly.

“We are pleased to announce approval of Acetaminophen, Aspirin and Caffeine Tablets, emphasizing our focus on building a sustainable OTC product portfolio in the US market.

We received approval for this triple combination product within 14 months from filing.

With this, we have received three ANDA approvals over the past month.” said Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals, Inc., commenting on the approval.

Acetaminophen, Aspirin and Caffeine Tablets are indicated for the treatment of migraine.

Granules now has a total of 38 ANDA approvals from USFDA (37 Final approvals and 1 tentative approval) Excedrin is a trademark of GSK Consumer Healthcare S.A.


Also read:

Sun Pharma to launch entire range of Epilepsy treatment drug in India

Dr Reddy’s launch Lansoprazole DR orally disintegrating tablets

Unichem gets USFDA approval for Apremilast Tablets

Lupin gets USFDA nod to market generic Droxidopa capsules

Aurobindo Pharma gets USFDA nod for generic Droxidopa capsules


The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Go to main website, click here

Follow and connect with us on Facebook and Linkedin

Subscribe for daily free updates, click here

For daily free updates on WhatsApp, click here

Subscribe here for daily updates
Loading